Edition:
India

Axovant Gene Therapies Ltd (AXGT.OQ)

AXGT.OQ on NASDAQ Stock Exchange Global Select Market

7.69USD
13 Sep 2019
Change (% chg)

$0.07 (+0.92%)
Prev Close
$7.62
Open
$7.54
Day's High
$7.80
Day's Low
$7.45
Volume
15,891
Avg. Vol
139,111
52-wk High
$20.80
52-wk Low
$3.82

Latest Key Developments (Source: Significant Developments)

Axovant Gene Therapies Appoints David Nassif As CFO
Monday, 1 Jul 2019 

July 1 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT APPOINTS DAVID NASSIF AS CHIEF FINANCIAL OFFICER AND EXPANDS BOARD OF DIRECTORS.AXOVANT GENE THERAPIES LTD - ANNOUNCED EXPANSION OF ITS BOARD OF DIRECTORS WITH ADDITION OF SENTHIL SUNDARAM.  Full Article

Axovant And Yposkesi Sign Strategic Gene Therapy Development And Manufacturing Partnership
Thursday, 20 Jun 2019 

June 20 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT AND YPOSKESI SIGN STRATEGIC GENE THERAPY DEVELOPMENT AND MANUFACTURING PARTNERSHIP.AXOVANT GENE THERAPIES LTD - YPOSKESI WILL PROVIDE EXPERTISE IN PROCESS DEVELOPMENT, TECHNOLOGY TRANSFER, MANUFACTURING SCALE-UP.AXOVANT GENE THERAPIES - SIGNED PARTNERSHIP WITH YPOSKESI FOR PREFERRED ACCESS AND RESERVED CAPACITY FOR CGMP GRADE VIRAL VECTOR PRODUCTION.AXOVANT GENE THERAPIES LTD - BY 2021, YPOSKESI PLANS TO INCREASE THIS FOOTPRINT TO 100,000 FT2.  Full Article

Axovant Announces 6-Mnth Follow-Up Data From 1st Cohort Of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD & Pipeline Update
Thursday, 6 Jun 2019 

June 6 (Reuters) - Axovant Gene Therapies Ltd ::AXOVANT ANNOUNCES 6-MONTH FOLLOW-UP DATA FROM FIRST COHORT OF SUNRISE-PD PHASE 2 TRIAL OF AXO-LENTI-PD AND PIPELINE UPDATE.AXOVANT GENE THERAPIES LTD - TOTALITY OF DATA ACROSS PROGRAM AT 6 MONTHS SUPPORTS OVERALL FAVORABLE PRODUCT PROFILE.AXOVANT GENE THERAPIES LTD - INITIAL THREE-MONTH DATA FROM SECOND DOSE COHORT OF SUNRISE-PD PHASE 2 STUDY IS EXPECTED IN Q4 OF 2019.AXOVANT GENE THERAPIES LTD - AXO-LENTI-PD WAS OBSERVED TO BE GENERALLY WELL TOLERATED AT SIX MONTHS.AXOVANT GENE THERAPIES LTD - AXO-LENTI-PD CONTINUED TO DEMONSTRATE BENEFITS IN BOTH PATIENTS ACROSS MULTIPLE MEASURES AFTER A SINGLE ADMINISTRATION.AXOVANT GENE THERAPIES LTD - TERMINATED LICENSE AND COLLABORATION AGREEMENT WITH BENITEC BIOPHARMA LIMITED IN ITS ENTIRETY.AXOVANT GENE THERAPIES - AXO-LENTI-PD HAD NO SERIOUS ADVERSE EVENTS RELATED TO PRODUCT OR PROCEDURE.  Full Article

Axovant Q2 Loss Per Share $0.28
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Axovant Sciences Ltd ::AXOVANT ANNOUNCES SECOND FISCAL QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.AXOVANT SCIENCES - AS OF SEPT 30, 2018, HAD $90.7 MILLION OF CASH, WORKING CAPITAL OF $47.4 MILLION, & LONG-TERM DEBT OF $33.3 MILLION.  Full Article

Patrick Machado Says Axovant Sciences Agreed To Sell To Roivant 14.3 Mln Shares
Thursday, 7 Jun 2018 

June 7 (Reuters) - Patrick Machado::PATRICK MACHADO SAYS ON JUNE 5, ROIVANT ENTERED SHARE PURCHASE AGREEMENT - SEC FILING.PATRICK MACHADO SAYS AXOVANT SCIENCES AGREED TO ISSUE, SELL TO ROIVANT 14.3 MILLION SHARES AT $1.75/ SHARE IN A PRIVATE PLACEMENT.PATRICK MACHADO SAYS ROIVANT PROVIDED FINANCING WITH AXOVANT'S ENTRY TO LICENSE AGREEMENT WITH OXFORD BIOMEDICA.PATRICK MACHADO - ROIVANT REMAINS DIRECT OWNER OF 89.3 MILLION SHARES OF AXOVANT, INCLUDING 75 MILLION SHARES BENEFICIALLY OWNED BEFORE AXOVANT’S IPO.PATRICK MACHADO SAYS SHARES DISPOSITIVE POWER OVER ROIVANT’S 89.3 MILLION SHARES OF AXOVANT WITH OTHER INDEPENDENT DIRECTOR OF ROIVANT CURRENTLY SERVING.  Full Article

Axovant Sciences Initiated Reduction In Its Workforce
Thursday, 15 Feb 2018 

Feb 14 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING.AXOVANT SCIENCES - ‍EXPECTS TO COMPLETE REDUCTION IN HEADCOUNT, EMPLOYEE TRANSFERS, INCLUDING PAYMENT OF EMPLOYEE SEVERANCE, BENEFITS, IN Q3 2018​.AXOVANT SCIENCES LTD - EXPECTS REALIGNMENT ACTIONS TO RESULT IN RESTRUCTURING CHARGE OF ABOUT $1.5 MILLION FOR EMPLOYEE SEVERANCE AND RELATED COSTS​.AXOVANT SCIENCES LTD - ‍ EXPECTS REALIGNMENT ACTIONS, CHANGES IN MANAGEMENT TO RESULT IN ANNUALIZED COST SAVINGS OF BETWEEN ABOUT $6.0 MILLION AND $8.0 MILLION​.  Full Article

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Thursday, 7 Dec 2017 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease
Tuesday, 26 Sep 2017 

Sept 26 (Reuters) - Axovant Sciences Ltd :At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition.Axovant Sciences - ‍announced that phase 3 mindset clinical trial of its investigational drug intepirdine did not meet its co-primary efficacy endpoints​.Axovant Sciences Ltd - ‍in study, intepirdine was generally well tolerated​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia remains on track to report topline results at end of 2017​.Axovant Sciences - ‍after 24 weeks of treatment, change from baseline in cognition was non-significantly improved in intepirdine arm versus placebo arm​.Axovant Sciences Ltd - ‍there was essentially no difference between intepirdine and placebo arms in change from baseline in activities of daily living​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia with lewy bodies remains on track to report topline results at end of 2017​.Axovant Sciences - ‍only endpoint in which any significant improvement was seen in intepirdine arm versus placebo arm was in first key secondary endpoint​.Axovant Sciences Ltd - ‍company will work with investigators to conclude mindset open-label extension study​.  Full Article